Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model



    HAE:TSX

    MONTREAL, Sept. 11 /CNW Telbec/ - Haemacure Corporation (TSX : HAE), a
Montreal-based specialty bio-therapeutics company developing high-value human
plasma-derived protein products for commercialization, disclosed today the
positive results of a second preclinical study conducted on the use of its
proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN,
in preventing the formation of post-surgical adhesions in a bleeding surgical
model.
    The study compared Haemacure's fibrin sealant to untreated controls, and
to two major FDA-approved adhesion prevention products: Interceed(TM)
Absorbable Adhesion Barrier (Ethicon) and Seprafilm(R) Adhesion Barrier
(Genzyme). Use of Haemacure's fibrin sealant in the presence of blood resulted
in a statistically significant reduction in the incidence, extent and severity
of adhesions, as compared to the untreated control group. Haemacure's fibrin
sealant also was statistically significantly more effective than both
Interceed and Seprafilm. For example, the extent of adhesions in both the
untreated and Seprafilm groups was three times (54.2%) that in the Haemacure's
fibrin sealant group (18%). It was even higher, four times, in the Interceed
group (71.7%). Liquid fibrin sealants, such as Haemacure's, are much easier to
apply to treatment sites than adhesion barriers such as Interceed. They also
lend themselves to laparoscopic application much better than these types of
barriers.
    This second study, conducted in July 2008, confirms and extends previous
pre-clinical results demonstrating the effectiveness of Haemacure's fibrin
sealant in adhesion prevention, using its current haemostasis formulation. The
previous study, conducted in April 2008, also demonstrated that the use of
Haemacure's fibrin sealant resulted in a statistically significant reduction
in the incidence, extent and severity of adhesions, as compared to untreated
controls. Both studies were designed to evaluate the efficacy of Haemacure's
fibrin sealant in a rabbit uterine horn abrasion model. The previous study
used a model where bleeding was absent or minimal.
    "We are very excited with the results of this latest study, as it opens a
new market with a significant unmet medical need and allows Haemacure to
leverage its technology, past clinical data and experience in a timely
manner", said Joseph Galli, Chairman and CEO of Haemacure.
    The use of Haemacure's current fibrin sealant haemostasis formulation for
adhesion prevention could significantly accelerate time to market for this
indication, by three to five years. This reduced timeframe accelerates
Haemacure's ability to address a significant unmet medical need with a
potential additional indication for its fibrin sealant. Post-surgical
adhesions are estimated to cost the U.S. healthcare system in excess of
$2.1 billion annually. The U.S. market for adhesion prevention products in
gynaecological surgery is estimated today at $100 million and could grow to
US$150-$200 million in fibrin sealant sales.

    About Haemacure

    Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical haemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III
clinical trials during the first half of calendar 2009. Haemacure's second
product candidate is thrombin, a component of its fibrin sealant, now in
preclinical stage. Follow-on development will focus on the use of fibrin
sealant in aesthetics, adhesion prevention, combination with biomaterials,
drug delivery, regenerative medecine, skin graft fixation for burn injuries,
and wound healing. Haemacure has identified eleven additional specialty
proteins and enzymes in one if its two plasma fractions and seeks to advance
these proteins and enzymes through partnerships with pharmaceutical and
biotechnology companies. Haemacure is headquartered in Montreal, Canada and
operates offices in Sarasota, Florida through a wholly-owned subsidiary. The
Corporation is traded under stock symbol HAE on the TSX.

    Forward-looking Statements

    Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. Haemacure disclaims any intention
or obligation to update these statements.




For further information:

For further information: Joseph Galli, Chairman and CE, Haemacure
Corporation, (514) 990-7074O, jgalli@haemacure.ca, www.haemacure.com; Gilles
Lemieux, Secretary, Haemacure Corporation, (514) 282-3350, ext. 22,
ir@haemacure.ca, www.haemacure.com

Organization Profile

HAEMACURE CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890